37 research outputs found

    Estimated continuous annual BCSM rates and hazard ratio of BCSM in certain subpopulations.

    No full text
    <p>(A) Patients were age<40 with ER negative and node positive diseases. (B) Patients were age≥60 with ER positive and node negative diseases.</p

    Annual BCSM rates and hazard ratio of BCSM in the total population and different subgroups.

    No full text
    <p>Annual BCSM rates and hazard ratio of BCSM in the total population and different subgroups.</p

    Filtration process.

    No full text
    <p>We identified 228209 female patients (20 and 84 yrs) diagnosed stages I to III unilateral invasive breast cancer between January 1, 1990, and December 31, 2005, through Surveillance, Epidemiology, and End Results (SEER) Program (<a href="http://www.seer.cancer.gov/" target="_blank">www.seer.cancer.gov</a>) SEER*Stat Database: Incidence—SEER 18 Regs Research Data released April 2015, based on the November 2014 submission.</p

    Compared with the cumulative disease free survival rate curve of invasive micropapillary carcinoma (IMPC) and invasive ductal carcinoma (IDC) (<i>P</i> = .606).

    No full text
    <p>Compared with the cumulative disease free survival rate curve of invasive micropapillary carcinoma (IMPC) and invasive ductal carcinoma (IDC) (<i>P</i> = .606).</p

    The pathologic characteristics between IMPC patients with and without recurrence.

    No full text
    1<p><b>IMPC:</b> invasive micropapillary carcinoma;</p>2<p><b>LVI:</b> Lymphovascular invasion;</p>3<p><b>G1:</b> Grade 1;</p>4<p><b>G2</b>: Grade 2;</p>5<p><b>G3:</b> Grade 3.</p><p>The pathologic characteristics between IMPC patients with and without recurrence.</p

    Pure and mixed invasive micropapillary carcinoma.

    No full text
    <p>Pure invasive micropapillary carcinoma, ×100 original magnification (A); Mixed carcinoma with IMPC (left up area) and invasive ductal carcinoma, not otherwise specified (right low area), ×40 original magnification (B).</p

    Disease free survival comparison of patients according to the semi-quantitative ER level in the whole group (<i>P</i> = .023) (A), IMPC group (<i>P</i> = .575) (B) and IDC group (<i>P</i> = .025) (C).

    No full text
    <p>Disease free survival comparison of patients according to the semi-quantitative ER level in the whole group (<i>P</i> = .023) (A), IMPC group (<i>P</i> = .575) (B) and IDC group (<i>P</i> = .025) (C).</p

    Baseline characteristics and treatment patterns for all patients.

    No full text
    1<p><b>IMPC:</b> invasive micropapillary breast carcinoma;</p>2<p><b>IDC:</b> invasive ductal carcinoma not otherwise specified;</p>3<p>*All the chi-square analysis has been tested by bootstrapping;</p>4<p>**Grading in IMPC and IDC was slightly different because IMPC was characterized by cells arranged in pseudopapillary structures, without typical ductal structure;</p>5<p><b>ER:</b> estrogen receptor status;</p>6<p><b>PR:</b> progesterone receptor status;</p>7<p><b>HER2/neu:</b> human epidermal growth factor receptor 2 status;</p>8<p><b>BCS:</b> breast-conservative surgery.</p><p>Baseline characteristics and treatment patterns for all patients.</p

    Cumulative disease free survival rate curve according to tumor size and lymph node status in invasive micropapillary carcinoma (IMPC) (<i>P</i><.001) and invasive ductal carcinoma (IDC) (<i>P</i> = .009).

    No full text
    <p>Cumulative disease free survival rate curve according to tumor size and lymph node status in invasive micropapillary carcinoma (IMPC) (<i>P</i><.001) and invasive ductal carcinoma (IDC) (<i>P</i> = .009).</p

    IMPC with lymphovascular invasion.

    No full text
    <p>Extensive lymphovascular invasion (LVI), ×100 original magnification (A); The endoepithelial cells were positive for D2-40 by immunohistochemical stain, ×100 original magnification (B).</p
    corecore